Hengdi Pharmaceuticals: Torasemide Injection Obtains Drug Registration Certificate.

Hengdi Pharmaceuticals announced that the company's Torasemide Injection has recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration. The drug is classified as a class 3 chemical drug, with specifications of 2ml: 10mg and 4ml: 20mg, with a shelf life of 18 months. Torasemide Injection is suitable for the long-term management of heart failure, liver cirrhosis, and renal edema, with the characteristics of being highly efficient and long-lasting. The acquisition of the drug registration certificate signifies that the company has the qualification to sell the drug in the domestic market, further enriching the company's product line. However, the uncertainty of whether the product can generate significant revenue still exists, and in the short term, it does not have a major impact on the company's performance.